Previous 10 | Next 10 |
Sol-Gel Technologies (NASDAQ: SLGL ): FY GAAP EPS of -$1.26 beats by $0.04 . More news on: Sol-Gel Technologies Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Top-line generic product revenue of $22.8 million in fiscal 2019 New Drug Applications for Epsolay ® and Twyneo ® remain on track for the second quarter and second half 2020, respectively NESS ZIONA, Israel, March 24, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd...
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences indus...
NESS ZIONA, Israel, March 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products fo...
The following slide deck was published by Sol-Gel Technologies Ltd. in conjunction with this Read more ...
NESS ZIONA, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, ...
Gainers : BioXcel Therapeutics (NASDAQ: BTAI ) +58% . More news on: BioXcel Therapeutics, Inc., Genprex, Inc., ImmunoGen, Inc., Stocks on the move, , Read more ...
Thinly traded Sol-Gel Technologies (NASDAQ: SLGL ) slumps 23% premarket on light volume in response to its public offering of ~2.1M ordinary shares and three-year warrants to purchase up to an aggregate of ~1.7M ordinary shares at a combined price of $11.00 per share and accomp...
NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for...
Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea Results pave the way for NDA submission in the second quarter of 2020 NESS ZIONNA, Israel, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technol...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...